Permanent Prostate Brachytherapy in Prostate Glands <20 cm3

Jyoti Mayadev, Gregory S. Merrick, Joshua R. Reed, Wayne M. Butler, Robert W. Galbreath, Zachariah A. Allen, Kent E. Wallner

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Purpose: To investigate the dosimetry, treatment-related morbidity, and biochemical outcomes for brachytherapy in patients with prostate glands <20 cm3. Methods and Materials: From November 1996 to October 2006, 104 patients with prostate glands <20 cm3 underwent brachytherapy. Multiple prostate, urethral, and rectal dosimetric parameters were evaluated. Treatment-related urinary and rectal morbidity were assessed from patient questionnaires. Cause-specific survival, biochemical progression-free survival, and overall survival were recorded. Results: The median patient age, follow up, and pre-treatment ultrasound volume was 64 years, 5.0 years and 17.6cm3, respectively. Median day 0 dosimetry was significant for the following: V100 98.5%, D90 126.1% and R100 <0.5% of prescription dose. The mean urethral and maximum urethral doses were 119.6% and 133.8% of prescription. The median time to International Prostate Symptom Score resolution was 4 months. There were no RTOG grade III or IV rectal complications. The cause-specific survival, biochemical progression-free survival, and overall survival rates were 100%, 92.5%, and 77.8% at 9 years. For biochemically disease-free patients, the median most recent postbrachytherapy PSA value was 0.02 ng/mL. Conclusion: Our results demonstrate that brachytherapy for small prostate glands is highly effective, with an acceptable morbidity profile, excellent postimplant dosimetry, acceptable treatment-related morbidity, and favorable biochemical outcomes.

Original languageEnglish (US)
Pages (from-to)1450-1455
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number5
DOIs
StatePublished - Apr 2010
Externally publishedYes

Keywords

  • Brachytherapy
  • Prostate cancer
  • Prostate size
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'Permanent Prostate Brachytherapy in Prostate Glands <20 cm<sup>3</sup>'. Together they form a unique fingerprint.

  • Cite this

    Mayadev, J., Merrick, G. S., Reed, J. R., Butler, W. M., Galbreath, R. W., Allen, Z. A., & Wallner, K. E. (2010). Permanent Prostate Brachytherapy in Prostate Glands <20 cm3 International Journal of Radiation Oncology Biology Physics, 76(5), 1450-1455. https://doi.org/10.1016/j.ijrobp.2009.04.014